Work

Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.5077

Authors: Praful Ravi, Charlene Mantia, Christopher Su, Karl Sorenson, Nityam Rathi, Ziad Bakouny, Neeraj Agarwal, Brian Addis Costello, Rana R. McKay, Vivek Narayan, Ajjai Shivaram Alva, Bradley Alexander McGregor, Xin Gao, David F. McDermott, Toni K. Choueiri

Institutions: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, U-M Rogel Cancer Center, Mayo Clinic, University of Utah, Huntsman Cancer Institute, University of Pennsylvania, Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Harvard University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3031048441

Cites:

Cited by: 1

Related to: 10